Ascopharm
Ascopharm is recorded as a service provider in 5 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 5 of 5 trials · Latest update first
A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (FORTIFI-HN01).
Sponsor Bicara Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease
Sponsor Not reported
- Start (EU)
- Latest update
- Estimated end
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Sponsor Corcept Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)
Sponsor Intensity Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Ascopharm?
The 2026-10-09 snapshot links Ascopharm to 5 distinct CTIS trials. Recorded services include Fees Reimbursement, Patient concierge, Patient expense reimbursement vendor for FRA and POL, patient reimbursement support, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ascopharm?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Blood Disorders, Gynecology, Otolaryngology. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ascopharm conducted?
The linked trials record locations in 12 countries, including France, Spain, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Ascopharm delivered services.
What can this page tell me about Ascopharm's trial experience?
Browse 5 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Ascopharm. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ascopharm
- Ascopharm GmbH